Display options
Cite
Alday-Parejo B, Richard F, Wörthmüller J, et al. MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. Cancers (Basel). 2020;12(1)doi: 10.3390/cancers12010223.
Alday-Parejo, B., Richard, F., Wörthmüller, J., Rau, T., Galván, J. A., Desmedt, C., Santamaria-Martinez, A., & Rüegg, C. (2020). MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. Cancers, 12(1), . https://doi.org/10.3390/cancers12010223
Alday-Parejo, Begoña, et al. "MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer." Cancers vol. 12,1 (2020). doi: https://doi.org/10.3390/cancers12010223
Alday-Parejo B, Richard F, Wörthmüller J, Rau T, Galván JA, Desmedt C, Santamaria-Martinez A, Rüegg C. MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. Cancers (Basel). 2020 Jan 16;12(1). doi: 10.3390/cancers12010223. PMID: 31963297; PMCID: PMC7016640.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jan 16;12(1). doi: 10.3390/cancers12010223.

MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer.

Cancers

Begoña Alday-Parejo, François Richard, Janine Wörthmüller, Tilman Rau, José A Galván, Christine Desmedt, Albert Santamaria-Martinez, Curzio Rüegg

Affiliations

  1. Laboratory of Experimental and Translational Oncology, Pathology, Department of Oncology, Microbiology and Immunology, Faculty of Sciences and Medicine, University of Fribourg, 1700 Fribourg, Switzerland.
  2. Laboratory for Translational Breast Cancer Research, KU Leuven, 3001 Leuven, Belgium.
  3. Institute of Pathology, University of Bern, 3008 Bern, Switzerland.
  4. Tumor Ecology Laboratory, Pathology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, 1700 Fribourg, Switzerland.

PMID: 31963297 PMCID: PMC7016640 DOI: 10.3390/cancers12010223

Abstract

Membrane-associated guanylate kinase (MAGUK) with inverted domain structure-1 (MAGI1) is an intracellular adaptor protein that stabilizes epithelial junctions consistent with a tumor suppressive function in several cancers of epithelial origin. Here we report, based on experimental results and human breast cancer (BC) patients' gene expression data, that MAGI1 is highly expressed and acts as tumor suppressor in estrogen receptor (ER)

Keywords: COX-2; MAGI1; breast cancer; estrogen receptor; inflammation; metastasis; prognosis; recurrence; stratification

Conflict of interest statement

The authors declare no conflict of interests.

References

  1. Biochem Biophys Res Commun. 2000 Apr 21;270(3):903-9 - PubMed
  2. Cancer Manag Res. 2018 Oct 26;10:4653-4667 - PubMed
  3. N Engl J Med. 2018 Jul 12;379(2):111-121 - PubMed
  4. J Clin Oncol. 1989 Sep;7(9):1239-51 - PubMed
  5. Sci Transl Med. 2015 Apr 15;7(283):283ra51 - PubMed
  6. Breast Cancer Res. 2011;13(6):221 - PubMed
  7. FASEB J. 2005 Jan;19(1):115-7 - PubMed
  8. Clin Cancer Res. 2007 Aug 15;13(16):4672-6 - PubMed
  9. Cancer Causes Control. 2011 Jul;22(7):965-75 - PubMed
  10. J Natl Cancer Inst. 2012 Feb 22;104(4):311-25 - PubMed
  11. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  12. J Clin Oncol. 2016 Jun 10;34(17):1995-2002 - PubMed
  13. Int J Biol Markers. 2013 Apr 23;28(1):E92-9 - PubMed
  14. J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 - PubMed
  15. N Engl J Med. 2019 May 16;380(20):1929-1940 - PubMed
  16. Front Med (Lausanne). 2018 Sep 04;5:248 - PubMed
  17. Cancer Discov. 2017 Feb;7(2):202-217 - PubMed
  18. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 - PubMed
  19. J Biol Chem. 2001 May 25;276(21):18563-9 - PubMed
  20. Chin J Cancer Res. 2017 Feb;29(1):25-35 - PubMed
  21. Clin Cancer Res. 2008 Aug 15;14(16):5158-65 - PubMed
  22. Breast Cancer Res Treat. 2007 Jan;101(2):191-7 - PubMed
  23. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 - PubMed
  24. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 - PubMed
  25. J Clin Oncol. 2019 Mar 10;37(8):624-635 - PubMed
  26. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e8-e21 - PubMed
  27. Nature. 2002 Jan 31;415(6871):530-6 - PubMed
  28. Nat Commun. 2016 May 10;7:11479 - PubMed
  29. Breast Cancer (Dove Med Press). 2017 Sep 20;9:537-550 - PubMed
  30. J Clin Oncol. 2010 Mar 20;28(9):1467-72 - PubMed
  31. Cancer Prev Res (Phila). 2011 Nov;4(11):1728-35 - PubMed
  32. Cancer Drug Resist. 2019;2:198-209 - PubMed
  33. Gut. 2006 Jan;55(1):115-22 - PubMed
  34. Exp Cell Res. 2002 May 1;275(2):155-70 - PubMed
  35. Oncogene. 2004 Oct 7;23(46):7669-78 - PubMed
  36. J Clin Oncol. 2006 Aug 10;24(23):3726-34 - PubMed
  37. Breast Cancer Res. 2018 Nov 20;20(1):142 - PubMed
  38. Oncogene. 2003 Sep 11;22(39):7998-8011 - PubMed
  39. Nat Med. 2008 May;14(5):518-27 - PubMed
  40. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  41. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3053-61 - PubMed
  42. J Clin Invest. 2013 Jul;123(7):2873-92 - PubMed
  43. J Clin Oncol. 2012 Jun 1;30(16):1996-2004 - PubMed
  44. N Engl J Med. 2016 Aug 25;375(8):717-29 - PubMed
  45. Front Immunol. 2012 Jan 12;2:98 - PubMed
  46. J Egypt Natl Canc Inst. 2013 Dec;25(4):181-91 - PubMed
  47. Semin Immunopathol. 2013 Mar;35(2):123-37 - PubMed
  48. Cancer Discov. 2012 Dec;2(12):1091-9 - PubMed
  49. Am J Cancer Res. 2015 Sep 15;5(10):2929-43 - PubMed
  50. Oncologist. 2007 Mar;12(3):253-70 - PubMed
  51. Cancer Cell. 2011 Nov 15;20(5):576-90 - PubMed
  52. J Clin Oncol. 2015 Mar 1;33(7):701-8 - PubMed
  53. PLoS One. 2011;6(7):e21800 - PubMed
  54. Cancer Causes Control. 2007 Aug;18(6):613-20 - PubMed
  55. Endocr Relat Cancer. 2015 Feb;22(1):R51-67 - PubMed
  56. Curr Treat Options Oncol. 2019 Nov 21;20(11):82 - PubMed
  57. Oncogene. 1999 Dec 16;18(54):7810-5 - PubMed
  58. J Natl Cancer Inst. 2018 Oct 1;110(10):1115-1122 - PubMed
  59. N Engl J Med. 2010 Nov 11;363(20):1938-48 - PubMed
  60. Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25 - PubMed
  61. Semin Cancer Biol. 2012 Jun;22(3):226-33 - PubMed
  62. J Biol Chem. 2002 Aug 16;277(33):30183-90 - PubMed
  63. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4686-91 - PubMed
  64. J Clin Oncol. 1996 Sep;14(9):2584-9 - PubMed
  65. Mediators Inflamm. 2013;2013:720536 - PubMed
  66. Br J Cancer. 2014 Jul 29;111(3):623-7 - PubMed
  67. Breast Care (Basel). 2016 Oct;11(5):339-344 - PubMed
  68. Nat Protoc. 2019 Mar;14(3):703-721 - PubMed
  69. Cancer Res. 1995 Aug 1;55(15):3331-8 - PubMed
  70. Oncologist. 2004;9(6):606-16 - PubMed
  71. Mol Endocrinol. 2012 Mar;26(3):360-71 - PubMed
  72. World J Clin Oncol. 2014 Aug 10;5(3):412-24 - PubMed
  73. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  74. Clin Cancer Res. 2013 Oct 1;19(19):5413-22 - PubMed
  75. Breast Cancer Res Treat. 2011 Feb;126(1):149-55 - PubMed
  76. J Invest Surg. 2012 Apr;25(2):93-9 - PubMed
  77. Genome Biol. 2007;8(8):R157 - PubMed
  78. N Engl J Med. 2019 Jun 20;380(25):2395-2405 - PubMed
  79. Cell. 2004 Jun 25;117(7):927-39 - PubMed
  80. Front Med (Lausanne). 2017 Dec 08;4:227 - PubMed
  81. Breast Cancer Res. 2011;13(6):224 - PubMed
  82. Biomed Environ Sci. 2015 Jul;28(7):502-9 - PubMed
  83. N Engl J Med. 2009 Feb 19;360(8):790-800 - PubMed
  84. Cancer Res. 1992 Mar 15;52(6):1399-405 - PubMed
  85. Dan Med J. 2016 May;63(5): - PubMed
  86. Nature. 1995 Dec 21-28;378(6559):785-9 - PubMed
  87. Mol Cancer Ther. 2014 Feb;13(2):444-53 - PubMed
  88. Carcinogenesis. 2011 Oct;32(10):1441-9 - PubMed
  89. Biologics. 2012;6:289-97 - PubMed
  90. Mol Cell Biol. 2002 Feb;22(4):1172-83 - PubMed
  91. J Virol. 2014 Jul;88(13):7155-69 - PubMed
  92. Clin Cancer Res. 2018 Aug 1;24(15):3717-3728 - PubMed
  93. Cell. 2015 Oct 8;163(2):506-19 - PubMed
  94. Oncogene. 2012 Jan 5;31(1):48-59 - PubMed

Publication Types

Grant support